Mullingar

Crohns disease is a chronic condition causing severe inflammation in the digestive tract, mainly affecting the bowels, and leading to symptoms like belly pain, diarrhea, tiredness, and weight loss. This trial is evaluating several targeted therapies for adults with moderate to severe Crohns disease. The study involves around 540 adults and aims to assess how well these treatments work and monitor any side effects over time. The treatments being studied include risankizumab, trosunilimab, lutikizumab, and ABBV-8736. These medicines are given either by injection under the skin or infusion into a vein, depending on the drug. Participants will be randomly assigned to receive one of several treatment combinations or monotherapies, with some continuing risankizumab alone for up to 72 weeks. Participants will attend regular hospital or clinic visits for medical assessments, blood tests, and endoscopies to check the effects of treatment. Researchers will also monitor side effects, collect daily diary information, and use questionnaires. Key outcomes include the percentage of participants achieving endoscopic remission by week 12 and tracking adverse events for up to about 96 weeks.